Price: $3.5200
$0.00
0.000%
|
Day's High:
| $3.52
| Week Perf:
| -0.28 %
|
Day's Low: |
$ 3.46 |
30 Day Perf: |
-9.74 % |
Volume (M): |
2 |
52 Wk High: |
$ 4.75 |
Volume (M$): |
$ 7 |
52 Wk Avg: |
$3.71 |
Open: |
$3.51 |
52 Wk Low: |
$2.89 |
|
|
Market Capitalization (Millions $) |
174 |
Shares
Outstanding (Millions) |
49 |
Employees |
194 |
Revenues (TTM) (Millions $) |
30 |
Net Income (TTM) (Millions $) |
-27 |
Cash Flow (TTM) (Millions $) |
290 |
Capital Exp. (TTM) (Millions $) |
0 |
Genfit S A
Genfit S is a biopharmaceutical company that specializes in the development of innovative therapies for patients with metabolic and liver-related diseases. The company's lead product candidate is elafibranor, which is a first-in-class drug being developed for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a chronic and progressive liver disease that is associated with obesity, insulin resistance, and other metabolic disorders. Genfit S is headquartered in France and has a strong pipeline of other innovative products in development. The company has a proprietary technology platform that allows it to develop drugs that can modulate the activity of nuclear receptors, which are important regulators of gene expression and metabolism. The company has a team of experienced scientists and researchers who are dedicated to the development of safe and effective therapies for patients with liver and metabolic diseases. Genfit S has established numerous partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies to advance its research and development efforts. Overall, Genfit S is a promising biopharmaceutical company that is leading the way in the development of innovative therapies for patients with liver and metabolic diseases. Its expertise in nuclear receptor modulation and strong pipeline of products makes it a company to watch in the biotech space.
Company Address: 885, avenue Eug?ne Avinée Loos 59120
Company Phone Number: 2016 4000 Stock Exchange / Ticker: NASDAQ GNFT
GNFT is expected to report next financial results on April 17, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Pharmacyte Biotech Inc
The Biotechnology and Pharmaceuticals industry insiders have begun to analyze the third-quarter earnings of 2024. As of now, the industry insiders have observed an operating loss of $-1.868946 million from a particular company, which has not yet disclosed any revenue for the period from November to January 31, 2024. In order to provide some context for the recent performance, it is worth comparing it to the same period in 2023, when the company reported an operating loss of $-1.552983 million. One of the notable observations from the third quarter of 2024 earnings season, apart from the absence of revenue, is the significant increase in net deficit. The company recorded a net deficit of $-1.401 million, which is considerably higher than the $-0.764 million reported in the corresponding financial reporting period a year ago.
|
Adverum Biotechnologies Inc
Adverum Biotechnologies Inc, a leading biotechnology and pharmaceutical company, has experienced a decrease in its stock by -19.05% in the preceding 30 days. Despite this decline, the year-to-date performance of the company stands at an impressive 105.29%. Currently trading on the NASDAQ, Adverum Biotechnologies Inc's stock is 31.8% above its 52-week average. During the earnings season from October to December 31, 2023, shareholders did not expect any moderations in the company's top-line performance. However, they were pleasantly surprised by the positive operating deficit of $-26.158 million during the same period. This improvement from the previous quarter's operating deficit of $-33.94 million has increased analysts' confidence in Adverum Biotechnologies Inc.
|
Zeo Scientifix Inc
Zeo Scientifix Inc has shown promising growth in its recent financial results, despite reporting a deficit per share of $-0.17 for the span ending January 31, 2024. This is a significant improvement from the deficit of $-2.287 million in the same period a year ago. The company's revenue also saw a healthy increase of 7.828% to $1.15 million, showing strong growth potential. One key highlight of the financial report is the notable increase in inventories and supplies, which now stand at $0.3 million. This indicates that the company is investing in its operations and preparing for future growth. Additionally, the decrease in accounts receivable compared to the previous year suggests that the company is effectively managing its cash flow and collections.
|
Cyclo Therapeutics Inc
Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, down from $-0.48 per share in the same reporting season the previous year. Unlike many other entities in the Biotechnology and Pharmaceuticals sectors, which are experiencing declining top-line and receding transactions, Cyclo Therapeutics Inc has managed to shine in the fourth quarter. This is a positive development for the company, as it signifies its ability to navigate obstacles and maintain growth.
|
Calidi Biotherapeutics Inc
In the world of biotechnology and pharmaceuticals, Calidi Biotherapeutics Inc has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-18.246049 million, a significant increase from the operating deficit of $-2.714765 million in the fourth quarter of 2022. The net deficit for the financial period ending December 31, 2023, was reported at $-20.699 million, a substantial increase from $-2.587 million in the previous year. Despite these losses, the company did not report any revenue for the financial year 2023, with a bottom-line of $-29.22 million.
|
Per Share |
Current |
Earnings (TTM) |
-0.54 $ |
Revenues (TTM) |
0.6 $
|
Cash Flow (TTM) |
5.86 $ |
Cash |
3.08 $
|
Book Value |
2.14 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.54 $
|
Revenues (TTM) |
0.6 $ |
Cash Flow (TTM) |
5.86 $ |
Cash |
3.08 $
|
Book Value |
2.14 $ |
Dividend (TTM) |
0 $ |
|
|
|
|